37 - Population screening for hemochromatosis  pp. 342-346

Population screening for hemochromatosis

By James C. Barton et al.

Image View Previous Chapter Next Chapter



Before the 1980s, hemochromatosis was thought to be an uncommon disorder, but severe iron overload was common in case series of white patients diagnosed to have “classical” hemochromatosis in medical care. A high proportion of 2851 hemochromatosis patients located using patient advocacy groups, physicians, blood centers, newsletters, and the internet reported on a questionnaire that they had symptoms or other problems that were interpreted as complications of iron overload. Thus, it was generally presumed for many years that most whites with hemochromatosis would eventually develop injurious iron overload. Accordingly, large-scale population screening using iron phenotyping of white populations was promoted to achieve early diagnosis and permit timely treatment to alleviate iron overload.

A pioneering screening study of 11,065 presumably healthy Utah blood donors revealed a high prevalence of hemochromatosis homozygotes defined by a persistently high serum transferrin saturation level and post-initial screening evaluations of iron stores. Since the description of the HFE gene in 1996, it has been possible to screen for the genotype HFE C282Y homozygosity (and serum iron measures) associated with “classical” hemochromatosis. Additional large-scale genetic screening studies have been performed in southern California, Norway, North America, and Australia. Outcomes of large-scale screening programs to detect HFE hemochromatosis and iron overload are summarized herein (Table 37.1). The potential value of targeted screening is also described.

Large-scale screening programs

Utah blood donors

In a landmark study of the 1980s, 11,065 presumably healthy volunteer blood donors in Utah were screened using an elevated transferrin saturation criterion.

Åsberg A , Hveem K , Kruger O , Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002; 37: 719–24.
Acton RT , Barton JC , Passmore LV , et al. Accuracy of family history of hemochromatosis or iron overload: The Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol 2008; 6: 934–8.
Adams PC , Passmore L , Chakrabarti S , et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006; 4: 918–23.
Adams PC , Reboussin DM , Barton JC , et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 17698.
Adams PC , Reboussin DM , Barton JC , et al. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Int J Lab Hematol 2008; 30: 300.
Adams PC , Reboussin DM , Press RD , et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med 2007; 120: 999–1007.
Allen KJ , Gurrin LC , Constantine CC , et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221–30.
Asberg A , Hveem K , Thorstensen K , et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 1108–15.
Asberg A , Tretli S , Hveem K , Bjerve KS. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol 2002; 37: 1212–19.
Bacon BR , Olynyk JK , Brunt EM , Britton RS , Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953–62.
Barton JC , Acton RT , Dawkins FW , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the Hemochromatosis and Iron Overload Screening Study. Genet Test 2005; 9: 231–41.
Barton JC , Acton RT , Leiendecker-Foster C , et al. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol 2008; 83: 126–32.
Barton JC , Acton RT , Lovato L , et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening Study. Clin Genet 2006; 69: 487.
Barton JC , Acton RT. Population screening for hemochromatosis: has the time finally come? Curr Gastroenterol Rep 2000; 2: 18–26.
Barton JC , Rothenberg BE , Bertoli LF , Acton RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89–93.
Beutler E , Felitti V , Gelbart T , Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.
Beutler E , Felitti VJ , Koziol JA, Ho NJ , Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis in the USA. Lancet 2002; 359: 211–18.
Edwards CQ , Carroll M , Bray P , Cartwright GE. Hereditary hemochromatosis. Diagnosis in siblings and children. N Engl J Med 1977; 297: 7–13.
Edwards CQ , Griffen LM , Goldgar D , Drummond C , Skolnick MH , Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62.
Hall MA , Barton JC , Adams PC , et al. Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract 2007; 56: 829–34.
Harris EL , McLaren CE , Reboussin DM , et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167: 722–6.
Hicken BL , Calhoun DA , Barton JC , Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test 2004; 8: 90.
McDonnell SM , Preston BL , Jewell SA , et al. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619–24.
Olynyk JK , Cullen DJ , Aquilia S , Rossi E , Summerville L , Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718–24.
Phatak PD , Ryan DH , Cappuccio J , et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002; 29: 41.
Phatak PD , Sham RL , Raubertas RF , et al. Prevalence of hereditary hemochromatosis in 16,031 primary care patients. Ann Intern Med 1998; 129: 954–61.
Power TE , Adams PC , Barton JC , et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007; 11: 55–64.
US Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145: 204–8.
Waalen J , Felitti VJ , Gelbart T , Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373–6.
Whitlock EP , Garlitz BA , Harris EL , Beil TL , Smith PR. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209–23.